

## SPECIFIEKE ZOEKSTRATEGIE NHG-STANDAARD ATRIUMFIBRILLEREN (M79)

*Oriënterende search, oktober 2011*

"Atrial Fibrillation"[Majr] AND ("randomized controlled trial"[pt] OR "systematic review"[tiab] OR "meta-analysis"[pt])

*Specifieke searches, oktober 2011*

"Atrial Fibrillation"[Mesh] AND ("Thromboembolism"[Mesh] OR thrombosis[mh] OR embolism[mh] OR "Stroke"[Mesh] OR "Ischemic Attack, Transient"[Mesh]) AND ("Risk Factors"[Mesh] OR "Risk Assessment"[Mesh]) AND ("Comparative Study"[Publication Type] OR "Retrospective Studies"[Mesh] OR "validation studies"[pt] OR "research support, non-U.S. gov't"[pt] OR "Follow-Up Studies"[Mesh] OR randomized[tw] OR randomised[tw]) AND CHADS\*[tiab]

"Atrial Fibrillation"[majr] AND ("rate control"[tiab] OR "RACE II"[tiab]) AND ("research support, non-U.S. Gov't"[pt] OR "comparative study"[pt] OR randomized[tw] OR randomised[tw])

"Atrial Fibrillation"[Mesh] AND ("rate control"[tiab] AND (strict[tiab] AND lenient[tiab]))

("Atrial Fibrillation/complications"[Mesh] OR "Atrial Fibrillation/drug therapy"[Mesh]) AND ("Anticoagulants/adverse effects"[Mesh] OR "Anticoagulants/therapeutic use"[Mesh]) AND ("Vitamin K/antagonists and inhibitors"[Mesh] OR "Fibrinolytic Agents"[Pharmacological Action] OR "Fibrinolytic Agents"[Mesh] OR "Pyrazoles"[Mesh] OR warfarin[mh]) AND (randomized[tw] OR randomised[tw] OR "research support, non-U.S. Gov't"[pt])

("Atrial Fibrillation"[mh] OR atrial fibrillation[tiab]) AND ((meta-analysis[pt] OR meta-anal\*[tw] OR metaanal\*[tw]) OR ("quantitative review"[tw] OR "systematic review"[tw] OR "methodologic review"[tw]) OR (review[pt] AND Cochrane[tw]) NOT (letter[pt] OR comment[pt] OR editorial[pt])) AND (("2012/09/01"[PDat] : "3000/12/31"[PDat]))

("Atrial Fibrillation"[mh] OR atrial fibrillation[tiab]) AND (randomized controlled trial[pt] OR random\*[tw] OR (double[tw] AND blind\*[tw]) OR placebo[tw]) AND (("2012/09/01"[PDat] : "3000/12/31"[PDat]))

*Extra searches, mei 2013*

(Atrial Fibrillation[Mesh] OR Atrial Fibrillation[tiab]) AND (novel oral anticoagulants[tiab] OR NOAC\*[tiab] OR "apixaban"[Supplementary Concept] OR "dabigatran"[Supplementary Concept] OR "rivaroxaban"[Supplementary Concept])

(Atrial Fibrillation[Mesh] OR Atrial Fibrillation[tiab]) AND (novel oral anticoagulants[tiab] OR NOAC\*[tiab] OR "apixaban"[Supplementary Concept] OR "dabigatran"[Supplementary Concept] OR "rivaroxaban"[Supplementary Concept]) NOT (meta-anal\*[tiab] OR systematic[tiab] OR randomized[tw])

(novel oral anticoagulants[tiab] OR NOAC\*[tiab] OR "apixaban"[Supplementary Concept] OR "dabigatran"[Supplementary Concept] OR "rivaroxaban"[Supplementary Concept]) AND ("Primary Health Care"[mh] OR "Family Practice"[mh] OR "family medicine"[tw] OR "general practice"[tw] OR "primary health care"[tw] OR "family practice"[tw] OR "primary care"[tw] OR primary care[tiab])

elderly[tw] AND (novel oral anticoagulants[tiab] OR NOAC\*[tiab] OR "apixaban"[Supplementary Concept] OR "dabigatran"[Supplementary Concept] OR "rivaroxaban"[Supplementary Concept])